About the Study

Low-Grade Glioma: A Study of the Drugs Selumetinib vs. Carboplatin/Vincristine

Study participants must be ages 2 through 21 and newly diagnosed or Previously Untreated Low-Grade Glioma (LGG). In this study, researchers want to if selumetinib works just as well as the standard treatment using carboplatin and vincristine (called CV) for patients with LGG. Selumetinib is a drug that works by blocking a protein (a basic building block of the human body) that lets cancer cells grow without stopping. Early studies have shown that selumetinib was successful in treating patients with LGG that came back after a first attempt at treatment. However, the use of selumetinib in patients with previously-untreated LGG is considered experimental because selumetinib has not yet been FDA approved for this type of cancer.

Interested in learning more?

Full Study Name: ACNS1833 - A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)